Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140016/S015

ZENITH ALPHA THORACIC ENDOVASCULAR GRAFT

Cook Medical Incorporated · Decision date Sep 18, 2025

FDA DECISIONP140016/S015

What did the FDA approve?

FDA records P140016/S015 as a supplement to PMA P140016, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 18, 2025.

FDA approval order statement

Approval for a change in coating for the delivery system of the Zenith Alpha 2 Thoracic Endovascular Graft
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Sep 18, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P140016/S015
Regulatory pathway
PMA supplement
Product code
MIH
Decision code
APPR
Decision date
Sep 18, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.

Product code
MIH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P140016/S015 received

    Application receipt date recorded by FDA.

  2. P140016/S015 · FDA decision

    Real-Time Process

  3. P140016/S016 · Related supplement

    Zenith Alpha Thoracic Endovascular Graft

  4. P140016/S017 · Related supplement

    Zenith Alpha Thoracic Endovascular Graft; Zenith Dissection Endovascular System

  5. P140016/S018 · Related supplement

    Zenith Alpha/ Alpha 2 Thoracic Endovascular Graft (ZTA/ZTA2)

Timeline entries are records held by MedtechLedger for P140016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140016

Explore the linked device profile

Other records with product code MIH

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cook Medical Incorporated

Headquarters
Not reported
Brand website
cookmedical.com
FDA applicant address
Sandet 6, Bjaeverskov, 4632

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records